CA3129955A1 - Hydroxypyridoxazepines as nrf2 activators - Google Patents
Hydroxypyridoxazepines as nrf2 activators Download PDFInfo
- Publication number
- CA3129955A1 CA3129955A1 CA3129955A CA3129955A CA3129955A1 CA 3129955 A1 CA3129955 A1 CA 3129955A1 CA 3129955 A CA3129955 A CA 3129955A CA 3129955 A CA3129955 A CA 3129955A CA 3129955 A1 CA3129955 A1 CA 3129955A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- dihydropyrido
- benzo
- triazol
- oxazepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806201P | 2019-02-15 | 2019-02-15 | |
| US62/806,201 | 2019-02-15 | ||
| US201962931877P | 2019-11-07 | 2019-11-07 | |
| US62/931,877 | 2019-11-07 | ||
| PCT/IB2020/051100 WO2020165776A1 (en) | 2019-02-15 | 2020-02-11 | Hydroxypyridoxazepines as nrf2 activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3129955A1 true CA3129955A1 (en) | 2020-08-20 |
Family
ID=69726636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3129955A Pending CA3129955A1 (en) | 2019-02-15 | 2020-02-11 | Hydroxypyridoxazepines as nrf2 activators |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11945826B2 (https=) |
| EP (1) | EP3924356A1 (https=) |
| JP (1) | JP7602469B2 (https=) |
| KR (1) | KR102932313B1 (https=) |
| CN (2) | CN113474349B (https=) |
| AU (1) | AU2020222080C1 (https=) |
| BR (1) | BR112021016042A2 (https=) |
| CA (1) | CA3129955A1 (https=) |
| CL (1) | CL2021002110A1 (https=) |
| CO (1) | CO2021010930A2 (https=) |
| IL (2) | IL313950A (https=) |
| MA (1) | MA54939A (https=) |
| MX (1) | MX2021009659A (https=) |
| MY (1) | MY209603A (https=) |
| PH (1) | PH12021551873A1 (https=) |
| SG (1) | SG11202108257TA (https=) |
| TW (2) | TWI843806B (https=) |
| WO (1) | WO2020165776A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3833662B1 (en) | 2018-08-20 | 2024-01-17 | Janssen Pharmaceutica NV | Inhibitors of keap1-nrf2 protein-protein interaction |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| KR102932313B1 (ko) * | 2019-02-15 | 2026-02-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 활성화제로서 히드록시피리드옥사제핀 |
| AU2020283361B2 (en) * | 2019-05-31 | 2025-11-27 | Ube Corporation | Benzotriazole derivative |
| CN118488944A (zh) | 2022-01-07 | 2024-08-13 | 中外制药株式会社 | 具有Nrf2活化作用的含氮杂环化合物 |
| US20250282724A1 (en) | 2022-04-28 | 2025-09-11 | Daiichi Sankyo Company, Limited | Benzotriazole compound |
| JPWO2023210740A1 (https=) | 2022-04-28 | 2023-11-02 | ||
| EP4580612A1 (en) * | 2022-09-02 | 2025-07-09 | Institut National de la Santé et de la Recherche Médicale | Use of nrf2 activators for the treatment of cerebral small vessel disease |
| CN121152792A (zh) | 2023-06-19 | 2025-12-16 | 中外制药株式会社 | 具有Nrf2活化作用的含氮杂环化合物的晶体 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7714012B2 (en) * | 2006-11-17 | 2010-05-11 | Trustees Of Dartmouth University | Synthesis and biological activities of new tricyclic-bis-enones (TBEs) |
| US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| CN104418834B (zh) * | 2013-08-23 | 2017-09-15 | 重庆博腾制药科技股份有限公司 | 一种抗糖尿病药物中间体的合成方法 |
| SG11201604611SA (en) | 2013-12-18 | 2016-07-28 | Glaxosmithkline Ip Dev Ltd | Nrf2 regulators |
| CN105272960A (zh) * | 2014-07-18 | 2016-01-27 | 上海科胜药物研发有限公司 | 一种坎格列净中间体2-(2-甲基-5-溴苄基)-5-(4-氟苯)噻吩的制备方法 |
| WO2016178148A1 (en) * | 2015-05-05 | 2016-11-10 | Glenmark Pharmaceuticals Limited | Process for preparation of dapagliflozin |
| CA2988373A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| WO2016203401A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| LT3307739T (lt) | 2015-06-15 | 2021-03-10 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 reguliatoriai |
| US10201531B2 (en) * | 2015-08-12 | 2019-02-12 | Mochida Pharmaceutical Co., Ltd. | Indazolyl-oxo-isothiazole compounds |
| US10364256B2 (en) * | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| US10913762B2 (en) * | 2016-01-27 | 2021-02-09 | Msn Laboratories Private Limited | Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof |
| CN108779108A (zh) * | 2016-12-06 | 2018-11-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途 |
| JP2020500918A (ja) * | 2016-12-12 | 2020-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのｎ−アリールピラゾール |
| ES2901617T3 (es) * | 2016-12-14 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Bisarilamidas como reguladores de NRF2 |
| CA3044773A1 (en) * | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activators |
| KR102932313B1 (ko) * | 2019-02-15 | 2026-02-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 활성화제로서 히드록시피리드옥사제핀 |
-
2020
- 2020-02-11 KR KR1020217029193A patent/KR102932313B1/ko active Active
- 2020-02-11 BR BR112021016042-6A patent/BR112021016042A2/pt unknown
- 2020-02-11 JP JP2021547429A patent/JP7602469B2/ja active Active
- 2020-02-11 CA CA3129955A patent/CA3129955A1/en active Pending
- 2020-02-11 EP EP20708180.3A patent/EP3924356A1/en active Pending
- 2020-02-11 AU AU2020222080A patent/AU2020222080C1/en active Active
- 2020-02-11 IL IL313950A patent/IL313950A/en unknown
- 2020-02-11 MA MA054939A patent/MA54939A/fr unknown
- 2020-02-11 US US17/429,088 patent/US11945826B2/en active Active
- 2020-02-11 SG SG11202108257TA patent/SG11202108257TA/en unknown
- 2020-02-11 PH PH1/2021/551873A patent/PH12021551873A1/en unknown
- 2020-02-11 CN CN202080014726.4A patent/CN113474349B/zh active Active
- 2020-02-11 CN CN202410206971.5A patent/CN118206566A/zh active Pending
- 2020-02-11 IL IL285438A patent/IL285438B2/en unknown
- 2020-02-11 WO PCT/IB2020/051100 patent/WO2020165776A1/en not_active Ceased
- 2020-02-11 MX MX2021009659A patent/MX2021009659A/es unknown
- 2020-02-11 MY MYPI2021004562A patent/MY209603A/en unknown
- 2020-02-13 TW TW109104455A patent/TWI843806B/zh active
- 2020-02-13 TW TW113112455A patent/TWI880702B/zh active
-
2021
- 2021-08-11 CL CL2021002110A patent/CL2021002110A1/es unknown
- 2021-08-19 CO CONC2021/0010930A patent/CO2021010930A2/es unknown
-
2024
- 2024-02-27 US US18/588,051 patent/US20240352034A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,254 patent/US20250313573A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102932313B1 (ko) | 2026-02-26 |
| CL2021002110A1 (es) | 2022-02-11 |
| MY209603A (en) | 2025-07-24 |
| MA54939A (fr) | 2021-12-22 |
| TWI843806B (zh) | 2024-06-01 |
| CO2021010930A2 (es) | 2021-09-09 |
| TW202045514A (zh) | 2020-12-16 |
| US20250313573A1 (en) | 2025-10-09 |
| CN113474349A (zh) | 2021-10-01 |
| JP2022520442A (ja) | 2022-03-30 |
| WO2020165776A1 (en) | 2020-08-20 |
| MX2021009659A (es) | 2021-09-08 |
| CN118206566A (zh) | 2024-06-18 |
| TWI880702B (zh) | 2025-04-11 |
| CN113474349B (zh) | 2024-03-01 |
| US20240352034A1 (en) | 2024-10-24 |
| US11945826B2 (en) | 2024-04-02 |
| AU2020222080C1 (en) | 2022-09-29 |
| IL313950A (en) | 2024-08-01 |
| IL285438B2 (en) | 2024-12-01 |
| US20220204526A1 (en) | 2022-06-30 |
| AU2020222080B2 (en) | 2022-05-19 |
| TW202440593A (zh) | 2024-10-16 |
| IL285438B1 (en) | 2024-08-01 |
| PH12021551873A1 (en) | 2022-05-23 |
| BR112021016042A2 (pt) | 2021-10-05 |
| EP3924356A1 (en) | 2021-12-22 |
| JP7602469B2 (ja) | 2024-12-18 |
| KR20210126676A (ko) | 2021-10-20 |
| SG11202108257TA (en) | 2021-08-30 |
| IL285438A (en) | 2021-09-30 |
| AU2020222080A1 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250313573A1 (en) | Hydroxypyridoxazepines as nrf2 activators | |
| US11459327B1 (en) | Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof | |
| CN106687450B (zh) | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 | |
| WO2022237843A1 (zh) | Axl抑制剂 | |
| EP3209652B1 (en) | Tricyclic atropisomer compounds | |
| JP2019532033A (ja) | オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物 | |
| CN121895290A (zh) | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 | |
| WO2005070884A2 (en) | Heterocyclic compounds useful as growth hormone secretagogues | |
| WO2016088082A1 (en) | Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof | |
| CN104470911A (zh) | 氨基甲酸酯/脲衍生物 | |
| CA3196059A1 (en) | Triazolopyridinyl compounds as kinase inhibitors | |
| WO2019224667A1 (en) | Indanes as nrf2 activators | |
| EP3555068A1 (en) | 3-oxo-1,4-diazepinyle compounds as nrf2 activators | |
| TW200823206A (en) | Thrombin receptor antagonists based on the modified tricyclic unit of himbacine | |
| JP6606806B2 (ja) | 重水素化キナゾリノン化合物及び該化合物を含む薬物組成物 | |
| RU2812931C2 (ru) | Гидроксипиридоксазепины в качестве активаторов nrf2 | |
| HK40106672A (zh) | 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯 | |
| CN121969620A (zh) | 作为激酶抑制剂的三唑并吡啶醚连接的化合物 | |
| KR20250040628A (ko) | 셀라스트롤 유도체 | |
| JP2016216446A (ja) | ピロリジン−２，５−ジオン誘導体の多形形態、医薬組成物、およびｉｄｏ１阻害薬としての使用方法 | |
| BR112019012300B1 (pt) | Composto ativador de nrf2, composição farmacêutica que compreende o mesmo e uso do dito composto para o tratamento de distúrbios respiratórios e não-respiratórios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220805 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240807 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241121 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241211 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250415 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250603 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250603 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260115 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260120 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260127 |